MEMPHIS, TN (January 29, 2015) – PMC Biogenix Inc. announces that effective February 1, 2015 or as contracts permit, prices for Armoslip and Kemamide brand primary and secondary fatty amides and bisamides will increase by 19.8% for all Euro denominated orders.
This increase is necessary to counter balance the unprecedented decline in the Euro to dollar exchange rate and preserve our ability to provide the world class service expected by our global customer base.
Customers with questions should contact their local sales manager or the PMC Biogenix customer service group.